


Financial Statements 2024-2025
Second Quarter
(Unaudited)



SQUARE PHARMACEUTICALS PLC.
(Consolidated and Separate)



SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

Consolidated Statement of Financial Position

As at 31 December 2024

| Particulars | Notes | 31 Dec 2024 Taka | 30 Jun 2024 Taka |
|---|-------|------------------------|------------------------|
| ASSETS | | | |
| Non-Current Assets: | | | |
| Property, Plant and Equipment | 02 | 30,161,061,265 | 27,750,005,864 |
| Investment in Associates | 03 | 19,063,882,673 | 17,397,060,559 |
| Investment in Marketable Securities | 04 | 9,830,546,374 | 9,292,402,647 |
| Long Term Investment - Others | 05 | 7,532,309,610 | 6,992,206,904 |
| | | 66,587,799,922 | 61,431,675,974 |
| Current Assets: | | | |
| Inventories | 06 | 14,592,316,388 | 12,582,152,295 |
| Trade and Other Receivables | 07 | 4,647,246,897 | 4,503,386,212 |
| Advances, Deposits and Prepayments | 08 | 1,991,084,233 | 2,106,522,837 |
| Cash and Cash Equivalents | 09 | 57,752,836,503 | 52,013,459,742 |
| | | 78,983,484,021 | 71,205,521,086 |
| TOTAL ASSETS | | 145,571,283,943 | 132,637,197,060 |
| EQUITY AND LIABILITIES | | | |
| EQUITY: | | | |
| Share Capital | | 8,864,510,100 | 8,864,510,100 |
| Share Premium | | 2,035,465,000 | 2,035,465,000 |
| General Reserve | | 105,878,200 | 105,878,200 |
| Fair Value Reserve | 10 | (167,909,431) | (275,040,481) |
| Tax Holiday Reserve | 11 | 1,674,592,803 | 951,511,612 |
| Translation Reserve | 12 | 124,606,724 | 97,906,017 |
| Retained Earnings | 13 | 116,359,875,096 | 114,139,071,906 |
| Attributable to Equity Holders | | 128,997,018,492 | 125,919,302,354 |
| Non-Controlling Interests | 14 | 3,870,404 | 2,318,478 |
| TOTAL EQUITY | | 129,000,888,896 | 125,921,620,832 |
| LIABILITIES: | | | |
| Non-Current Liabilities | | | |
| Long Term Loan | 15.1 | 510,219,792 | 814,539,826 |
| Deferred Tax Liabilities | 16 | 569,086,141 | 619,081,523 |
| | | 1,079,305,933 | 1,433,621,349 |
| Current Liabilities | | | |
| Long Term Loan - Current Portion | 15.2 | 620,439,578 | 614,539,826 |
| Trade Payables | | 1,325,420,965 | 1,455,428,272 |
| Other Payables | 17 | 11,822,935,739 | 1,820,943,973 |
| Current Tax Liabilities | 18 | 1,274,954,392 | 912,265,905 |
| Accrued Expenses | 19 | 261,226,667 | 286,793,273 |
| Unclaimed Dividend | | 186,111,773 | 191,983,630 |
| | | 15,491,089,114 | 5,281,954,879 |
| TOTAL LIABILITIES | | 16,570,395,047 | 6,715,576,228 |
| TOTAL EQUITY AND LIABILITIES | | 145,571,283,943 | 132,637,197,060 |
| Net Assets Value (NAV) per Share | 30 | 145.52 | 142.05 |

The annexed notes form an integral part of these financial statements.

Sd/-

Samuel S Chowdhury
Chairman

Sd/-

Mrs. Ratna Patra
Vice-Chairman

Sd/-

Tapan Chowdhury
Managing Director

Sd/-

Muhammad Zahangir Alam
Chief Financial Officer

Sd/-

Khandaker Habibuzzaman
Company Secretary



SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

Consolidated Statement of Profit or Loss and Other Comprehensive Income For the Quarter Ended 31 December 2024

| Particulars | Notes | Six-Month Result | | 2nd Quarter Result | |
|---|-------|------------------|------------------|--------------------|-----------------|
| | | July'24 - Dec'24 | July'23 - Dec'23 | Oct'24 - Dec'24 | Oct'23 - Dec'23 |
| | | Taka | Taka | Taka | Taka |
| Net Revenue | 20 | 37,717,778,672 | 35,552,503,593 | 19,970,891,107 | 17,741,265,448 |
| Cost of Goods Sold | 21 | (19,893,431,304) | (18,084,962,081) | (11,064,971,566) | (9,429,269,449) |
| Gross Profit | | 17,824,347,368 | 17,467,541,512 | 8,905,919,541 | 8,311,995,999 |
| Selling and Distribution Expenses | 22 | (6,045,429,884) | (5,270,833,021) | (2,987,891,424) | (2,788,716,297) |
| Administrative Expenses | 23 | (884,315,155) | (829,829,307) | (444,968,847) | (456,234,011) |
| Finance Cost | 24 | (127,200,832) | (99,669,079) | (58,405,306) | (58,267,267) |
| Operating Expenses | | (7,056,945,871) | (6,200,331,407) | (3,491,265,577) | (3,303,217,575) |
| Profit before Other Operating Income | | 10,767,401,497 | 11,267,210,105 | 5,414,653,964 | 5,008,778,424 |
| Other Operating Income | 25 | 227,776,534 | 128,427,559 | 16,521,154 | 12,880,353 |
| Profit from Operations | | 10,995,178,031 | 11,395,637,664 | 5,431,175,118 | 5,021,658,777 |
| Income from Investments | 26 | 3,056,110,856 | 2,137,688,825 | 1,591,890,211 | 1,050,282,114 |
| Profit before contribution to WPPF & WWF | | 14,051,288,887 | 13,533,326,489 | 7,023,065,329 | 6,071,940,891 |
| Contribution to WPPF & WWF | 27 | (665,805,097) | (652,184,353) | (332,994,252) | (292,113,630) |
| Profit before Tax | | 13,385,483,790 | 12,881,142,136 | 6,690,071,077 | 5,779,827,261 |
| Current Tax (Expense) | | (2,424,802,712) | (2,565,675,430) | (1,213,618,964) | (1,060,140,659) |
| Deferred Tax (Expense) / Income | | 68,899,866 | (82,124,872) | 29,440,774 | (126,999,229) |
| Income Tax Expense | 28 | (2,355,902,846) | (2,647,800,302) | (1,184,178,190) | (1,187,139,888) |
| Profit after Tax | | 11,029,580,944 | 10,233,341,834 | 5,505,892,887 | 4,592,687,373 |
| Profit from Associate Undertakings | 03 | 1,666,822,114 | 1,012,618,795 | 1,097,859,900 | 652,559,010 |
| Profit for the Period | | 12,696,403,058 | 11,245,960,629 | 6,603,752,787 | 5,245,246,383 |
| Net Unrealised Gain/(Loss) on Marketable Securities | 29 | 107,125,409 | 1,314,074 | (612,157,967) | (86,329,886) |
| Translation Adjustment for the Period | 12 | 26,700,706 | (62,349,088) | (115,257) | (36,283,929) |
| Other Comprehensive Income | | 133,826,115 | (61,035,014) | (612,273,224) | (122,613,815) |
| Total Comprehensive Income | | 12,830,229,173 | 11,184,925,615 | 5,991,479,563 | 5,122,632,568 |
| Profit for the Period Attributable to: | | | | | |
| Equity Holders of the Company | | 12,694,845,491 | 11,245,360,669 | 6,602,927,921 | 5,244,982,421 |
| Non-Controlling Interest | | 1,557,567 | 599,960 | 824,866 | 263,962 |
| | | 12,696,403,058 | 11,245,960,629 | 6,603,752,787 | 5,245,246,383 |
| Total Comprehensive Income Attributable to: | | | | | |
| Equity Holders of the Company | | 12,828,677,248 | 11,184,325,831 | 5,990,666,397 | 5,122,368,636 |
| Non-Controlling Interest | | 1,551,925 | 599,784 | 813,166 | 263,932 |
| | | 12,830,229,173 | 11,184,925,615 | 5,991,479,563 | 5,122,632,568 |
| Earnings Per Share (EPS) | 31 | 14.32 | 12.69 | 7.45 | 5.92 |

The annexed notes form an integral part of these financial statements.

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Mrs. Ratna Patra
Vice-Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

Consolidated Statement of Changes in Equity

For the Quarter Ended 31 December 2024

| Particulars | Attributable to Equity Holders | | | | | | | | Non-Controlling Interests | Total Equity |
|-------------------------------|--------------------------------|-----------------------|-------------------------|----------------------------|-----------------------------|-----------------------------|---------------------------|------------------------|---------------------------|------------------------|
| | Share Capital Taka | Share Premium Taka | General Reserve Taka | Fair Value Reserve Taka | Tax Holiday Reserve Taka | Translation Reserve Taka | Retained Earnings Taka | Total Taka | | |
| As At 01 July 2023 | 8,864,510,100 | 2,035,465,000 | 105,878,200 | 734,507,296 | 133,398,880 | (16,905,546) | 103,339,085,459 | 115,195,939,389 | 709,376 | 115,196,648,765 |
| Profit for the Period | - | - | - | - | - | - | 11,245,360,669 | 11,245,360,669 | 599,960 | 11,245,960,629 |
| Other Comprehensive Income | - | - | - | 1,314,249 | - | (62,349,088) | - | (61,034,839) | (176) | (61,035,015) |
| Tax Holiday Reserve | - | - | - | - | 333,831,164 | - | (333,831,164) | - | - | - |
| Cash Dividend (2022-23) | - | - | - | - | - | - | (9,307,735,605) | (9,307,735,605) | - | (9,307,735,605) |
| As At 31 December 2023 | 8,864,510,100 | 2,035,465,000 | 105,878,200 | 735,821,545 | 467,230,044 | (79,254,634) | 104,942,879,360 | 117,072,529,615 | 1,309,160 | 117,073,838,775 |
| As At 01 July 2024 | 8,864,510,100 | 2,035,465,000 | 105,878,200 | (275,040,481) | 951,511,612 | 97,906,017 | 114,139,071,906 | 125,919,302,354 | 2,318,478 | 125,921,620,832 |
| Profit for the Period | - | - | - | - | - | - | 12,694,845,491 | 12,694,845,491 | 1,557,567 | 12,696,403,058 |
| Other Comprehensive Income | - | - | - | 107,131,050 | - | 26,700,707 | - | 133,831,757 | (5,641) | 133,826,116 |
| Tax Holiday Reserve | - | - | - | - | 723,081,191 | - | (723,081,191) | - | - | - |
| Cash Dividend (2023-24) | - | - | - | - | - | - | (9,750,961,110) | (9,750,961,110) | - | (9,750,961,110) |
| As At 31 December 2024 | 8,864,510,100 | 2,035,465,000 | 105,878,200 | (167,909,431) | 1,674,592,803 | 124,606,724 | 116,359,875,096 | 128,997,018,492 | 3,870,404 | 129,000,888,896 |

The annexed notes form an integral part of these financial statements

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Mrs. Ratna Patra
Vice-Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

Consolidated Statement of Cash Flows

For the Quarter Ended 31 December 2024

| Particulars | Notes | July'24 - Dec'24 Taka | July'23 - Dec'23 Taka |
|---|-------|--------------------------|--------------------------|
| Cash Flows from Operating Activities: | | | |
| Receipts from Customers | | 43,488,770,640 | 42,181,114,091 |
| Receipts from Others | | 35,222,668 | 122,141,625 |
| Payments to Suppliers | | (16,232,342,292) | (11,043,718,090) |
| Payments for Manufacturing and Operating Expenses | | (11,553,272,186) | (11,578,598,715) |
| Payment of Value Added Tax | | (5,888,888,824) | (5,302,400,768) |
| Cash Generated from Operations | | 9,849,490,006 | 14,378,538,143 |
| Interest Paid | | (132,285,858) | (103,323,442) |
| Payment of Income Tax | | (1,862,114,225) | (1,875,910,781) |
| Payment of WPPF & WF | | (536,159,925) | (575,771,720) |
| Others | | 16,578,750 | 917,047,821 |
| Net Cash from Operating Activities | | 7,335,508,748 | 12,740,580,021 |
| Cash Flows from Investing Activities: | | | |
| Purchase of Property, Plant and Equipment | | (3,467,778,772) | (854,972,553) |
| Proceeds from Sale of Property, Plant and Equipment | | 22,309,353 | - |
| Long Term Investment - Others | | (540,102,706) | (1,939,594,992) |
| Investment in Marketable Securities | | (318,920,914) | (3,774,550,312) |
| Interest Received | | 2,708,416,424 | 1,762,743,936 |
| Dividends Received | | 127,564,112 | 14,816,295 |
| Net Cash from/(Used in) Investing Activities | | (1,468,512,503) | (4,791,557,626) |
| Cash Flows from Financing Activities: | | | |
| Payment of Dividend | | (5,871,856) | (8,508,143) |
| Proceeds from/Payment of Term Loan and Bank Overdraft | | (298,420,282) | (371,406,157) |
| Net Cash Used in Financing Activities | | (304,292,138) | (379,914,300) |
| Net Increase/(Decrease) in Cash and Cash Equivalents | | 5,562,704,107 | 7,569,108,095 |
| Cash and Cash Equivalents at 01 July | 09 | 52,013,459,742 | 50,094,321,854 |
| Effect of Exchange Rate Fluctuations on Cash and Cash Equivalents | | 176,672,654 | (226,201) |
| Cash and Cash Equivalents at 31 December | 09 | 57,752,836,503 | 57,663,203,748 |
| Net Operating Cash Flow (NOCF) per Share | 32 | 8.28 | 14.37 |

The annexed notes form an integral part of these financial statements.

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Mrs. Ratna Patra
Vice-Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary

**SQUARE PHARMACEUTICALS PLC.**

AND ITS SUBSIDIARIES

**Notes to the Consolidated Financial Statements
For the Quarter Ended 31 December 2024****01. Basis of Preparation of the Interim Financial Statements:**

These Financial Statements are the unaudited consolidated interim Financial Statements of Square Pharmaceuticals PLC., a company incorporated in Bangladesh under Companies Act, 1913; Square Pharmaceuticals Kenya EPZ Ltd., incorporated in Kenya under Companies Act, 2015, Kenya; Square Lifesciences Ltd., incorporated in Bangladesh under Companies Act, 1994, and Samson Pharma Inc., incorporated under Revised Corporation Code of the Philippines, 2019 for the 2nd Quarter Ended on December 31, 2024. These are prepared in accordance with IAS 34 - 'Interim Financial Reporting'. These financial statements should be read in conjunction with the Annual Financial Statements as of June 30, 2024, as they provide an update of previously reported information.

The accounting policies and presentation used are consistent with those used in the Annual Financials, except where noted below, Where necessary, the comparative figures have been reclassified or extended from the previously reported Interim Financial Statements to take into account any presentational changes made in the Annual Financial Statements or in these Interim Financial Statements.

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of revenue, expenses, assets, liabilities and disclosure of contingent liabilities at the date of the Interim Financial Statement. If in the future such estimates and assumptions, which are based on management's best judgement at the date of the Interim Financial Statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The management understand that the business is growing every year that means the assets are performing according to the intention of procurement and the discounted future cash flow from the operation of the assets would be positive if disposed at reporting date. At present, there is no intention to dispose these assets. Therefore, it is not required to record the impairment gain.

The company operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the reporting period.

The company has no reportable operating segments as per IFRS-8.

Figures have been rounded off to the nearest Taka.

Foreign Currency Translation:

The Financials of Square Pharmaceuticals Kenya EPZ Ltd. have been drawn in KHS (Kenyan Shilling) as reporting currency in Kenya. These Financials are converted in BDT to consolidate with the Financials of Square Pharmaceuticals PLC. as the parent company. 1 KES = 0.928127 BDT as at 31 December 2024.

02. Consolidated Property, Plant and Equipment: Tk. 30,161,061,265**Cost:**

| | 31 Dec 2024 | 30 Jun 2024 |
|--|-----------------------|-----------------------|
| Opening Balance | 50,654,228,044 | 47,837,735,674 |
| Translation Adjustments to opening balance | 42,228,621 | 221,339,254 |
| Addition during the Period/Year | 813,804,304 | 2,918,957,136 |
| | 51,510,260,969 | 50,978,032,064 |
| Disposal/Transfer during the Period/Year | (45,031,480) | (323,804,020) |
| Tk. | 51,465,229,489 | 50,654,228,044 |

Accumulated Depreciation:

| | | |
|--|-----------------------|-----------------------|
| Opening Balance | 25,796,547,715 | 23,576,848,855 |
| Translation Adjustments to opening balance | 8,422,472 | 31,894,803 |
| Charged for the Period/Year | 1,069,944,207 | 2,318,653,384 |
| | 26,874,914,394 | 25,927,397,042 |
| Disposal/Transfer during the Period/Year | (31,408,767) | (130,849,327) |
| Tk. | 26,843,505,627 | 25,796,547,715 |

Net Book Value

| | | |
|---|-----------------------|-----------------------|
| Consolidated Property, Plant and Equipment in Transit (Note - 02.1) | 24,621,723,862 | 24,857,680,329 |
| Consolidated Building under Construction (Note - 02.2) | 991,882,044 | 1,118,740,924 |
| Consolidated Capital Work-in-Progress (Note - 02.3) | 4,546,714,674 | 1,773,584,611 |
| | 740,685 | - |
| Tk. | 30,161,061,265 | 27,750,005,864 |

02.1 Consolidated Property, Plant and Equipment in Transit: Tk. 991,882,044

| | | |
|---------------------------------|--------------------|----------------------|
| Opening Balance | 1,118,740,924 | 715,369,536 |
| Addition during the Period/Year | 584,331,742 | 1,134,336,770 |
| | 1,703,072,666 | 1,849,706,306 |
| Transfer during the Period/Year | (711,190,622) | (730,965,382) |
| Tk. | 991,882,044 | 1,118,740,924 |

02.2 Consolidated Building under Construction: Tk. 4,546,714,674

| | | |
|---------------------------------|----------------------|----------------------|
| Opening Balance | 1,773,584,611 | 1,081,705,847 |
| Addition during the Period/Year | 2,773,130,063 | 1,063,055,568 |
| | 4,546,714,674 | 2,144,761,415 |
| Transfer during the Period/Year | - | (371,176,804) |
| Tk. | 4,546,714,674 | 1,773,584,611 |

02.3 Consolidated Capital Work-in-Progress:: Tk. 740,685

| | | |
|---------------------------------|----------------|-----------|
| Opening Balance | - | 859,697 |
| Addition during the Period/Year | 740,685 | - |
| | 740,685 | 859,697 |
| Transfer during the Period/Year | - | (859,697) |
| Tk. | 740,685 | - |

03. Consolidated Investment in Associates: Tk. 19,063,882,673

| | | |
|--|--------------------------|-----------------------|
| Opening Balance | 17,397,060,559.00 | 15,076,807,755 |
| Add: Profit/(Loss) during the Period/Year: | | |
| Square Textiles PLC. | 317,274,180.00 | 501,534,080 |
| Square Fashions Ltd. | 1,210,993,332.00 | 1,858,942,218 |
| Square Hospitals Ltd. | 138,554,602.00 | 234,086,537 |
| | 1,666,822,114.00 | 2,594,562,835 |
| Less: Dividend received during the Period/Year | - | (274,310,031) |
| Tk. | 19,063,882,673.00 | 17,397,060,559 |

Proportion of Ownership

| |
|--------|
| 46.36% |
| 48.63% |
| 49.94% |

04. Consolidated Investment in Marketable Securities: Tk. 9,830,546,374**04.1 Cost: Tk. 10,028,095,911**

| | | |
|---------------------------------|-----------------------|----------------------|
| Opening Balance | 9,615,982,078 | 3,773,747,813 |
| Addition during the Period/Year | 529,119,524 | 5,944,648,543 |
| Sold during the Period/Year | (117,005,691) | (102,414,278) |
| Tk. | 10,028,095,911 | 9,615,982,078 |

04.2 Market Value: Tk. 9,830,546,374

| | | |
|---------------------------------|----------------------|----------------------|
| Opening Balance | 9,292,402,647 | 4,589,867,031 |
| Addition during the Period/Year | 748,342,337 | 4,814,862,652 |
| Sold during the Period/Year | (210,198,610) | (112,327,036) |
| Tk. | 9,830,546,374 | 9,292,402,647 |

| | 31 Dec 2024 | 30 Jun 2024 |
|---|-----------------------|-----------------------|
| 05. Consolidated Long Term Investment - Others: Tk. 7,532,309,610 | | |
| 05.1 Ordinary Shares (Unquoted): Tk. 127,694,430 | | |
| (i) United Hospital Ltd. (120,000 Ordinary Shares of Tk.100/- each) | 12,000,000 | 12,000,000 |
| (ii) Central Depository Bangladesh Limited (5,711,804 Ordinary Shares of Tk. 10/- each) | 15,694,430 | 15,694,430 |
| (iii) FAM - First Fixed Income Fund (1,000 Units of Tk. 100,000/- each) | 100,000,000 | 100,000,000 |
| Tk. | 127,694,430 | 127,694,430 |
| 05.2 Non-Convertible Zero Coupon Bonds: Tk. 304,615,180 | | |
| (i) LankaBangla Finance Ltd. | - | 67,033,336 |
| (ii) Brac Bank Ltd. (200 Bonds) | 187,659,050 | 238,677,650 |
| (iii) IDLC Finance Ltd. (240 Bonds) | 116,956,130 | 158,801,488 |
| Tk. | 304,615,180 | 464,512,474 |
| 05.3 Non-Convertible Subordinated Bonds: Tk. 7,100,000,000 | | |
| (i) Mutual Trust Bank Ltd. (220 Bonds) | 2,200,000,000 | 2,200,000,000 |
| (ii) Southeast Bank Ltd. (3,000 Bonds) | 300,000,000 | 400,000,000 |
| (iii) Islami Bank Bangladesh Ltd. (30 Bonds) | 300,000,000 | 400,000,000 |
| (iv) Trust Bank Ltd. (30 Bonds) | 300,000,000 | 400,000,000 |
| (v) Eastern Bank Ltd. (50 Bonds) | 500,000,000 | 500,000,000 |
| (vi) Prime Bank Ltd. (100 Bonds) | 1,000,000,000 | 1,000,000,000 |
| (vii) Dutch Bangla Bank Ltd. (150 Bonds) | 1,500,000,000 | 1,500,000,000 |
| (viii) Shahjalal Islami Bank PLC. (1000 Bonds) | 1,000,000,000 | - |
| Tk. | 7,100,000,000 | 6,400,000,000 |
| Tk. | 7,532,309,610 | 6,992,206,904 |
| 06. Consolidated Inventories: Tk. 14,592,316,388 | | |
| Raw Materials | 5,455,115,936 | 4,801,972,525 |
| Packing Materials | 1,693,669,381 | 1,272,032,952 |
| Work-in-Process | 940,413,948 | 784,057,550 |
| Finished Goods | 4,901,624,434 | 3,825,932,863 |
| Spares & Accessories | 1,310,145,769 | 1,044,608,061 |
| Goods- in-Transit | 291,346,920 | 853,548,344 |
| Tk. | 14,592,316,388 | 12,582,152,295 |
| 07. Consolidated Trade and Other Receivables: Tk. 4,647,246,897 | | |
| Trade Receivables | 2,567,860,697 | 2,551,026,541 |
| Other Receivables (Note - 7.1) | 2,079,386,200 | 1,952,359,671 |
| Tk. | 4,647,246,897 | 4,503,386,212 |
| 07.1 Consolidated Other Receivables: Tk. 2,079,386,200 | | |
| Interest Receivable from Fixed Deposit Receipts | 1,647,266,098 | 1,520,761,823 |
| Interest Receivable from Short Notice Deposits | 7,462,258 | 1,300 |
| Gain against Zero Coupon Bonds (Receivable) | 69,529,676 | 87,443,698 |
| Interest Receivable from Subordinated Bonds | 58,210,958 | 47,324,767 |
| Accrued Income | 66,917,210 | 66,828,083 |
| Insurance Claim Receivable | 230,000,000 | 230,000,000 |
| Tk. | 2,079,386,200 | 1,952,359,671 |
| 08. Consolidated Advances, Deposits and Prepayments: Tk. 1,991,084,233 | | |
| 08.1 Advances: Tk. 1,018,098,459 | | |
| Employees | 289,167,467 | 283,810,814 |
| Advance Income Tax | 14,738,457 | 214,738,457 |
| Land Purchase | 91,044,000 | 84,081,400 |
| Suppliers | 623,148,535 | 616,316,380 |
| Tk. | 1,018,098,459 | 1,198,947,051 |
| 08.2 Deposits: Tk. 912,824,494 | | |
| Value Added Tax | 488,222,883 | 387,160,183 |
| Earnest Money & Security Deposit | 389,324,749 | 405,903,499 |
| Others | 35,276,862 | 13,001,014 |
| Tk. | 912,824,494 | 806,064,696 |
| 08.3 Prepayments: Tk. 60,161,280 | | |
| Office Rent | 23,032,440 | 23,242,440 |
| Insurance Premium | 37,128,840 | 78,268,650 |
| Tk. | 60,161,280 | 101,511,090 |
| Tk. | 1,991,084,233 | 2,106,522,837 |
| 09. Cash and Cash Equivalents: Tk. 57,752,836,503 | | |
| 09.1 Cash in Hand | | |
| 09.2 Cash at Bank: Tk. 26,041,268,163 | | |
| Current Accounts | 313,107,981 | 112,392,110 |
| STD & SND Accounts | 15,009,772,474 | 14,182,411,481 |
| Export Retention Quota Accounts (held in USD) | 179,425,856 | 174,360,222 |
| Margin Held Accounts (held in USD) | 601,856,167 | 525,205,243 |
| Dividend Accounts | 9,937,105,686 | 191,983,630 |
| Tk. | 26,041,268,163 | 15,186,352,686 |
| 09.3 Fixed Deposit Receipts (FDRs): Tk. 31,559,989,167 | | |
| FDRs held in BDT | 27,500,381,792 | 33,000,381,792 |
| FDRs held in USD | 4,059,607,375 | 3,819,836,939 |
| Tk. | 31,559,989,167 | 36,820,218,731 |
| Tk. | 57,752,836,503 | 52,013,459,742 |
| 10. Consolidated Fair Value Reserve: Tk. (167,909,431) | | |
| Opening Balance | (275,040,481) | 734,507,296 |
| Add: Unrealised Gain/(Loss) on Marketable Securities for the Period/Year (Note - 29) | 126,036,530 | (1,139,696,255) |
| Less: Current Period/Year's Deferred Tax (Expense)/Income (Note - 29) | (18,905,480) | 130,148,478 |
| Closing Balance | (167,909,431) | (275,040,481) |
| Tk. | (167,909,431) | (275,040,481) |

| | 31 Dec 2024 | 30 Jun 2024 |
|--|------------------------|------------------------|
| 11. Consolidated Tax Holiday Reserve: Tk. 1,674,592,803 | | |
| Opening Balance | 951,511,612 | 133,398,880 |
| Add: Transferred from Retained Earnings (Note - 13) | 723,081,191 | 818,112,732 |
| Closing Balance | 1,674,592,803 | 951,511,612 |
| 12. Consolidated Translation Reserve: Tk. 124,606,724 | | |
| Opening Balance | 97,906,017.00 | (16,905,546) |
| Translation Adjustment for the Period/Year | 26,700,707.00 | 114,811,563 |
| Closing Balance | 124,606,724.00 | 97,906,017 |
| 13. Consolidated Retained Earnings: Tk. 116,359,875,096 | | |
| Opening Balance | 114,139,071,906 | 103,339,085,459 |
| Add: Net Profit attributable to Equity Holders | 12,694,845,491 | 20,925,834,784 |
| Less: Transferred to Tax Holiday Reserve (Note - 11) | (723,081,191) | (818,112,732) |
| Less: Cash Dividend | (9,750,961,110) | (9,307,735,605) |
| Closing Balance | 116,359,875,096 | 114,139,071,906 |
| 14. Non Controlling Interest: Tk. 3,870,404 | | |
| Opening Balance | 2,318,478.00 | 709,376.00 |
| Add: Net Profit attributable to Non Controlling Interest | 1,557,567.00 | 1,611,137.00 |
| Add: Unrealised Gain/(Loss) on Marketable Securities | (5,641.00) | (2,035.00) |
| Closing Balance | 3,870,404.00 | 2,318,478.00 |
| 15. Consolidated Loans and Borrowings: Tk. 1,130,659,370 | | |
| Term Loan - Non Current Portion (Note - 15.1) | 510,219,792 | 814,539,826 |
| Term Loan - Current Portion (Note - 15.2) | 620,439,578 | 614,539,826 |
| | 1,130,659,370 | 1,429,079,652 |
| 15.1 Term Loan - Non Current Portion: Tk. 510,219,792 | | |
| a) Standard Chartered Bank, Kenya | 110,219,792 | 214,539,826 |
| b) Standard Chartered Bank, Bangladesh | 400,000,000 | 600,000,000 |
| | 510,219,792 | 814,539,826 |
| 15.2 Term Loan - Current Portion: Tk. 620,439,578 | | |
| a) Standard Chartered Bank, Kenya | 220,439,578 | 214,539,826 |
| b) Standard Chartered Bank, Bangladesh | 400,000,000 | 400,000,000 |
| | 620,439,578 | 614,539,826 |
| 16. Consolidated Deferred Tax Liabilities: Tk. 569,086,141 | | |
| Deferred Tax - Property, Plant and Equipment: | | |
| a) Square Pharmaceuticals PLC. (Note-16.1a) | 612,920,573 | 673,568,392 |
| b) Square Lifesciences Ltd. (Note-16.1b) | (14,202,001) | (5,949,954) |
| | 598,718,572 | 667,618,439 |
| Deferred Tax - Marketable Securities (Note-16.2) | (29,632,431) | (48,536,915) |
| | 569,086,141 | 619,081,524 |
| 16.1 Deferred Tax - Property, Plant and Equipment: | | |
| a) Square Pharmaceuticals PLC.: Tk. 612,920,573 | | |
| Carrying Amount | 12,059,773,395 | 12,418,606,865 |
| Tax Base | 9,335,681,959 | 9,424,969,566 |
| Taxable/(Deductible) Temporary Difference | 2,724,091,436 | 2,993,637,299 |
| Tax Rate | 22.50% | 22.50% |
| Closing Liabilities | 612,920,573 | 673,568,392 |
| Opening Liabilities | (673,568,392) | (944,474,683) |
| Current Period/Year's Expense/(Income) | (60,647,819) | (270,906,291) |
| b) Square Lifesciences Ltd.: Tk. (14,202,001) | | |
| Carrying Amount | 2,507,573,257 | 2,644,054,308 |
| Tax Base | 2,765,791,451 | 2,860,416,259 |
| Taxable/(Deductible) Temporary Difference | (258,218,194) | (216,361,951) |
| Tax Rate | 5.50% | 2.75% |
| Closing Liabilities | (14,202,001) | (5,949,954) |
| Opening Liabilities | 5,949,954 | 3,932,825 |
| Current Period/Year's Expense/(Income) | (8,252,047) | (2,017,129) |
| * Property, plant and equipment excluding Lands, PPE in transit and assets under construction. | | |
| 16.2 Deferred Tax - Marketable Securities: Tk. (29,632,431) | | |
| Carrying Amount | 9,830,546,374 | 9,292,402,647 |
| Tax Base | 10,028,095,912 | 9,615,982,078 |
| Taxable/(Deductible) Temporary Difference | (197,549,538) | (323,579,431) |
| Tax Rate | 15.00% | 15.00% |
| Closing Liabilities | (29,632,431) | (48,536,915) |
| Opening Liabilities | (48,536,915) | (81,611,922) |
| Current Period/Year's Expense/(Income) | (78,169,346) | (130,148,837) |
| 17. Consolidated Other Payables: Tk. 11,822,935,739 | | |
| Sundry Creditors | 633,983,548 | 539,395,363 |
| Income Tax (Deduction at Source) | 73,662,872 | 41,974,116 |
| Retention Money | 50,493,658 | 50,300,089 |
| Dividend Payable | 9,750,961,110 | - |
| Workers' Profit Participation Fund and Welfare Fund | 1,289,772,051 | 1,160,126,879 |
| Interest Payable | 24,062,500 | 29,147,526 |
| | 11,822,935,739 | 1,820,943,973 |
| 18. Consolidated Current Tax Liabilities: Tk. 1,274,954,392 | | |
| Opening balance | 912,265,905 | 356,095,553 |
| Provision for the Period/Year | 2,424,802,712 | 4,661,815,173 |
| Tax Paid (including Advance Income Tax) during the Period/Year | (2,062,114,225) | (4,105,644,821) |
| | 1,274,954,392 | 912,265,905 |
| 19. Consolidated Accrued Expenses: Tk. 261,226,667 | | |
| Accrued Expenses | 261,226,667 | 285,502,944 |
| Audit Fees | 100,000 | 1,290,329 |
| | 261,226,667 | 286,793,273 |

| | July'24 - Dec'24 | July'23 - Dec'23 |
|---|-----------------------|-----------------------|
| 20. Consolidated Net Revenue: Tk. 37,717,778,672 | | |
| Square Pharmaceuticals PLC. (Note - 20.1) | 29,813,582,142 | 31,033,879,297 |
| Square Lifesciences Ltd. (Note - 20.2) | 7,603,042,538 | 4,456,288,766 |
| Square Pharmaceuticals Kenya EPZ Ltd. | 301,153,992 | 62,335,530 |
| Tk. | 37,717,778,672 | 35,552,503,593 |
| 20.1 Square Pharmaceuticals PLC.: Tk. 29,813,582,142 | | |
| Local: | | |
| Gross Revenue | 33,911,148,340 | 36,293,651,905 |
| Value Added Tax | (4,378,353,682) | (5,256,967,590) |
| Revenue without VAT | 29,532,794,658 | 31,036,684,315 |
| Discount | (1,112,071,225) | (1,173,029,422) |
| Net Revenue - Local | 28,420,723,433 | 29,863,654,893 |
| Export Revenue - Equivalent to US \$11,661,087 (Jul'23-Dec'23: US \$11,525,880) | 1,392,858,710 | 1,170,224,404 |
| Tk. | 29,813,582,142 | 31,033,879,297 |
| 20.2 Square Lifesciences Ltd.: Tk. 7,603,042,538 | | |
| Local: | | |
| Gross Revenue | 9,451,191,757 | 5,524,567,855 |
| Value Added Tax | (1,409,472,442) | (818,651,445) |
| Revenue without VAT | 8,041,719,315 | 4,705,916,410 |
| Discount | (451,195,597) | (252,616,817) |
| Net Revenue - Local | 7,590,523,718 | 4,453,299,593 |
| Export Revenue - Equivalent to US \$105,155 (Jul'23-Dec'23: US \$27,468) | 12,518,820 | 2,989,173 |
| Tk. | 7,603,042,538 | 4,456,288,766 |
| 21. Consolidated Cost of Goods Sold: Tk. 19,893,431,304 | | |
| Raw Materials Consumed (Note - 21.1) | 9,185,208,744 | 8,135,298,387 |
| Packing Materials Consumed (Note - 21.2) | 4,587,058,592 | 3,833,404,290 |
| Cost of Materials Consumed | 13,772,267,336 | 11,968,702,677 |
| Add: Manufacturing Overhead (Note - 21.3) | 5,557,998,552 | 4,692,912,189 |
| Total Manufacturing Cost | 19,330,265,888 | 16,661,614,866 |
| Add: Opening Work-in-Process | 784,057,550 | 643,978,545 |
| Less: Closing Work-in-Process | (940,413,948) | (706,539,938) |
| Cost of Goods Manufactured | 19,173,909,490 | 16,599,053,473 |
| Add: Opening Finished Goods | 3,825,932,863 | 3,596,262,767 |
| Add: Purchase of Finished Goods | 1,937,318,643 | 1,736,673,630 |
| Less: Cost of Physician Sample | (142,105,258) | (112,724,181) |
| Cost of Goods Available for Sale | 24,795,055,738 | 21,819,265,689 |
| Less: Closing Finished Goods | (4,901,624,434) | (3,734,303,608) |
| Tk. | 19,893,431,304 | 18,084,962,081 |
| 21.1 Consolidated Raw Materials Consumed: Tk. 9,185,208,744 | | |
| Opening Stock | 4,801,972,525 | 4,784,438,787 |
| Purchase during the Period | 9,838,352,155 | 7,961,295,529 |
| Closing Stock | (5,455,115,936) | (4,610,435,929) |
| Tk. | 9,185,208,744 | 8,135,298,387 |
| 21.2 Consolidated Packing Materials Consumed: Tk. 4,587,058,592 | | |
| Opening Stock | 1,272,032,952 | 1,437,690,908 |
| Purchase during the Period | 5,008,695,021 | 3,660,336,051 |
| Closing Stock | (1,693,669,381) | (1,264,622,669) |
| Tk. | 4,587,058,592 | 3,833,404,290 |
| 21.3 Consolidated Manufacturing Overhead: Tk. 5,557,998,552 | | |
| Salaries & Allowances | 1,717,327,815 | 1,413,625,782 |
| Contribution to Provident Fund | 50,425,732 | 31,678,309 |
| Entertainment, Staff Lunch & Refreshments | 97,210,332 | 77,773,815 |
| Training & Development | 636,753 | 356,224 |
| Staff Uniform | 68,417,875 | 63,996,935 |
| Travelling & Conveyance | 34,395,656 | 27,289,259 |
| US FDA User Fees | 82,628,520 | 73,149,378 |
| Laboratory Consumables | 413,135,902 | 364,716,854 |
| Research and Product Development | 192,012,460 | 64,987,466 |
| Printing & Stationery | 48,798,252 | 47,295,178 |
| Courier, Telephone, Cell phone & Internet | 5,143,423 | 5,028,516 |
| Rental Expenses | 5,556,495 | 605,110 |
| Utilities Expense | 736,655,557 | 667,587,404 |
| Sanitation Expenses | 125,497,349 | 78,953,156 |
| Petrol, Oil & Lubricants | 223,087,824 | 107,273,899 |
| Generator Rental Expenses | 18,000,000 | 7,300,000 |
| Repairs & Maintenance - Factory | 636,507,031 | 554,717,406 |
| Repairs & Maintenance - Vehicle | 61,171,837 | 57,262,452 |
| Insurance Premium | 30,695,479 | 24,524,534 |
| Security Services | 41,990,553 | 31,975,427 |
| Govt. Taxes & License Fees | 15,800,254 | 16,834,811 |
| Toll Charges | 81,819,230 | 36,412,074 |
| Software, Hardware Support & VSAT Services | 33,653,217 | 27,135,809 |
| Depreciation | 836,122,804 | 912,174,720 |
| Other Expenses | 1,308,202 | 257,671 |
| Tk. | 5,557,998,552 | 4,692,912,189 |

| | July'24 - Dec'24 | July'23 - Dec'23 |
|--|----------------------|----------------------|
| 22. Consolidated Selling and Distribution Expenses: Tk. 6,045,429,884 | | |
| Salaries & Allowances | 946,381,969 | 838,583,397 |
| Contribution to Provident Fund | 78,042,481 | 60,994,263 |
| Entertainment, Staff Lunch & Refreshments | 22,240,509 | 15,339,082 |
| Training & Development | 5,838,983 | 4,956,575 |
| Staff Uniform | 3,518,860 | 3,173,253 |
| Travelling & Conveyance | 89,216,063 | 86,468,101 |
| Printing & Stationery | 49,425,366 | 43,723,162 |
| Courier, Telephone, Cell phone & Internet | 49,894,682 | 40,969,944 |
| Office and Godown Rent | 18,981,083 | 16,581,826 |
| Utilities Expense | 25,531,125 | 22,245,556 |
| Sanitation Expenses | 10,897,599 | 10,313,091 |
| Field Staff Salaries, Allowances, TA & DA | 1,984,655,468 | 1,817,318,112 |
| Target Incentive to Field Staff | 243,752,482 | 252,665,874 |
| Promotional Expenses | 563,300,475 | 516,819,052 |
| Marketing Expenses | 607,188,114 | 335,496,810 |
| Pharmacovigilance | 34,073,829 | 49,495,956 |
| Marketing Website Platform Software Maintenance | 7,535,633 | 5,651,840 |
| Event, Programs and Conference | 146,957,044 | 172,064,370 |
| Literature and Publications | 88,184,557 | 108,021,022 |
| Market Research & Survey Expenses | 12,661,447 | 9,247,561 |
| Advertisement | 756,000 | 130,000 |
| Delivery & Packing Expenses | 157,344,848 | 136,289,408 |
| Export Expenses | 166,430,399 | 85,605,851 |
| Repairs & Maintenance - Office | 35,899,902 | 32,919,121 |
| Repairs & Maintenance - Vehicle | 302,250,877 | 273,765,181 |
| Insurance Premium | 3,162,593 | 2,939,048 |
| Security Services | 56,537,996 | 47,617,220 |
| Govt. Taxes & License Fees | 26,519,661 | 18,327,656 |
| Bank Charges | 8,181,733 | 8,708,194 |
| Software, Hardware Support & VSAT Services | 37,763,617 | 26,517,737 |
| Depreciation | 113,389,371 | 114,963,266 |
| Other Expenses | 148,915,118 | 112,921,492 |
| Tk. | 6,045,429,884 | 5,270,833,021 |
| 23. Consolidated Administrative Expenses: Tk. 884,315,155 | | |
| Salaries & Allowances | 292,382,742 | 262,263,484 |
| Contribution to Provident Fund | 7,482,640 | 5,954,709 |
| Directors' Remuneration | 44,437,500 | 44,437,500 |
| Entertainment, Staff Lunch & Refreshments | 39,045,477 | 35,589,139 |
| Training & Development | 3,288,068 | 3,019,293 |
| Staff Uniform | 904,725 | 851,579 |
| Travelling & Conveyance | 90,163,957 | 80,098,529 |
| Printing & Stationery | 10,642,980 | 9,844,967 |
| Courier, Telephone, Cell phone & Internet | 6,628,549 | 5,004,918 |
| Office Rent | 14,341,364 | 10,172,688 |
| Utilities Expense | 16,995,909 | 14,075,250 |
| Sanitation Expenses | 5,588,248 | 4,769,009 |
| Subscription and Donation | 2,615,200 | 2,435,000 |
| Legal & Professional Fees | 4,006,439 | 1,704,081 |
| Repairs & Maintenance - Office | 103,570,053 | 89,162,270 |
| Repairs & Maintenance - Vehicle | 43,819,490 | 44,754,375 |
| Insurance Premium | 14,562,520 | 15,848,694 |
| Security Services | 33,670,507 | 27,013,780 |
| Govt. Taxes & License Fees | 15,390,161 | 38,232,093 |
| Bank Charges | 3,702,559 | 5,364,674 |
| Software & Hardware Support Services | 4,469,501 | 5,355,675 |
| Depreciation | 120,432,032 | 114,571,004 |
| Other Expenses | 6,174,534 | 9,306,596 |
| Tk. | 884,315,155 | 829,829,307 |
| 24. Consolidated Finance Cost: Tk. 127,200,832 | | |
| Square Pharmaceuticals PLC. | 6,203 | 16,325 |
| Square Lifesciences Ltd. | 50,891,574 | 57,089,527 |
| Square Pharmaceuticals Kenya EPZ Ltd. | 76,303,055 | 42,563,227 |
| Tk. | 127,200,832 | 99,669,079 |
| 25. Consolidated Other Operating Income: Tk. 227,776,534 | | |
| Rental Income | 987,708 | 876,706 |
| Sale of Scrap | 30,972,838 | 26,181,401 |
| Gain on Fluctuation of Foreign Currency | 183,778,097 | 78,183,399 |
| Cash Incentive Received against Export | 2,417,200 | 22,924,800 |
| P.F Forfeiture Amount | 934,049 | 261,253 |
| Gain/(Loss) on Disposal of Property, Plant and Equipment | 8,686,642 | - |
| Tk. | 227,776,534 | 128,427,559 |
| 26. Consolidated Income from Investments: Tk. 3,056,110,856 | | |
| Interest from Deposits | 1,810,992,019 | 1,472,360,382 |
| Interest from Short Notice Deposits | 671,593,561 | 407,895,069 |
| Gain on Redemption of Zero Coupon Bond | 17,688,683 | 34,547,098 |
| Interest from Subordinate Bonds | 335,079,562 | 207,217,424 |
| Dividend Income | 127,564,112 | 14,816,295 |
| Gain on Marketable Securities (Realized) | 93,192,919 | 852,558 |
| Tk. | 3,056,110,856 | 2,137,688,825 |
| 27. Consolidated Allocation for WPPF & WF: Tk. 665,805,097 | | |
| Square Pharmaceuticals PLC. | 500,933,068 | 590,332,841 |
| Square Lifesciences Ltd. | 164,872,029 | 61,851,512 |
| Tk. | 665,805,097 | 652,184,353 |

| | July'24 - Dec'24 | July'23 - Dec'23 |
|---|------------------------|------------------------|
| 28. Consolidated Income Tax Expense: Tk. 2,355,902,846 | | |
| Current Tax Expense: | | |
| Square Pharmaceuticals PLC. | 2,234,244,820 | 2,526,922,772 |
| Square Lifesciences Ltd. | 190,557,892 | 38,752,658 |
| | 2,424,802,712 | 2,565,675,430 |
| Deferred Tax Expense/(Income): | | |
| Square Pharmaceuticals PLC. | (60,647,819) | 83,766,623 |
| Square Lifesciences Ltd. | (8,252,047) | (1,641,751) |
| | (68,899,866) | 82,124,872 |
| Tk. | 2,355,902,846 | 2,647,800,302 |
| 29. Consolidated Unrealised Gain/(Loss) on Marketable Securities: Tk. 107,125,409 | | |
| Closing Unrealised Gain/(Loss) | (174,700,135) | 817,579,300 |
| Less: Opening Unrealised Gain/(Loss) | (300,730,028) | 816,119,218 |
| | 126,029,893 | 1,460,082 |
| Less: Related Deferred Tax | (18,904,484) | (146,008) |
| Tk. | 107,125,409 | 1,314,074 |
| 30. Consolidated Net Asset Value (NAV) per Share: Tk. 145.52 | | |
| Net Asset attributable to the Ordinary Shareholders | 128,997,018,492 | 125,919,302,354 |
| Number of Shares outstanding | 886,451,010 | 886,451,010 |
| Net Asset Value (NAV) per Share | 145.52 | 142.05 |
| 31. Consolidated Earnings per Share (EPS): Tk. 14.32 | | |
| Profit for the Period | 12,696,403,058 | 11,245,960,629 |
| Number of Shares outstanding | 886,451,010 | 886,451,010 |
| Earnings per Share (EPS) | 14.32 | 12.69 |
| 32. Consolidated Net Operating Cash Flow (NOCF) per Share: Tk. 8.28 | | |
| Net Cash Generated from Operating Activities (Note - 32.1) | 7,335,508,748 | 12,740,580,021 |
| Number of Shares outstanding | 886,451,010 | 886,451,010 |
| Net Operating Cash Flow (NOCF) per Share | 8.28 | 14.37 |
| Due to Eid holiday in June 2023, additional credit facility were provided to the local customers which were collected during July'23 - Dec'23. Additionally, the Company received Insurance claim against the fire incident of LVP. These two factors caused a spike in the NOCF per share in July'23- Dec'23. There is no such factors in this period. Therefore, the NOCF per share seen a decline in the current period. | | |
| 32.1 Consolidated Reconciliation of Net Profit with Net Cash Generated from Operating Activities: | | |
| Profit for the Period | 12,696,403,058 | 11,245,960,629 |
| Adjustments for: | | |
| Non-Cash Income/Expenses: | | |
| Depreciation | 1,069,944,207 | 1,141,708,990 |
| Effect of Exchange Rate Fluctuations on Cash and Cash Equivalents | (210,478,803) | 226,201 |
| Profit from Associate Undertakings | (1,666,822,114) | (1,012,618,795) |
| Translation Adjustments | 26,700,706 | (62,349,088) |
| Deferred Tax (Expense) / Income | (68,899,866) | 82,124,872 |
| | (849,555,870) | 149,092,180 |
| Non-Operating Income/Expenses: | | |
| Income from Investments (Note - 26) | (3,056,110,856) | (2,137,688,825) |
| Gain/(Loss) on Disposal of Property, Plant and Equipment (Note - 25) | (8,686,642) | - |
| | (3,064,797,498) | (2,137,688,825) |
| Changes in Working Capital: | | |
| (Increase)/Decrease in Inventories | (2,010,164,093) | (32,901,685) |
| (Increase)/Decrease in Trade Receivables | (16,834,156) | 581,132,314 |
| (Increase)/Decrease in Other Receivables | (89,127) | 961,655,427 |
| (Increase)/Decrease in Advances, Deposits and Prepayments | 122,401,204 | (1,257,096,192) |
| Increase/(Decrease) in Trade Payables | (130,007,307) | 2,381,678,885 |
| Increase/(Decrease) in Other Payables | 251,030,656 | 8,614,000 |
| Increase/(Decrease) in Current Tax Liabilities | 362,688,487 | 689,370,288 |
| Increase/(Decrease) in Accrued Expenses | (25,566,606) | 150,763,002 |
| | (1,446,540,942) | 3,483,216,037 |
| Net Cash from Operating Activities | 7,335,508,748 | 12,740,580,021 |
| 33. Consolidated Contingent Liabilities: | | |
| Liabilities for at Sight Letter of Credit as of 31 December 2024: | | |
| a) Square Pharmaceuticals PLC.: Tk. 7,283,395,575. | | |
| b) Square Lifesciences Ltd.: Tk. 201,805,272. | | |
| 34. Related Party Transactions: | | |
| A. Associates: | | |
| Square Textiles PLC. (46.36% share): | | |
| Opening Balance | - | - |
| Addition during the Period | 5,386,200,000 | 3,217,925,000 |
| Realized during the Period | (5,386,200,000) | (1,738,773,000) |
| Closing Balance | - | 1,479,152,000 |
| Square Fashions Ltd. (48.63% share): | | |
| Opening Balance | - | - |
| Addition during the Period | 11,975,938,570 | 3,420,675,220 |
| Realized during the Period | (11,975,938,570) | (3,461,324,042) |
| Closing Balance | - | (40,648,822) |
| Square Hospitals Ltd. (49.94% Shares): | | |
| Opening Balance | - | - |
| Addition during the Period | 22,759,766 | 19,156,379 |
| Paid during the Period | (22,753,808) | (19,156,379) |
| Closing Balance (Payable) | 5,958 | - |

B. Subsidiaries of Associates:**Square Denims Ltd. (Subsidiary of Square Fashions Ltd.):**

Opening Balance
Addition during the Period
Realized during the Period
Closing Balance

| | July'24 - Dec'24 | July'23 - Dec'23 |
|-----|------------------|------------------|
| | - | - |
| | 840,702,503 | 842,621,288 |
| | (840,702,503) | (842,621,288) |
| Tk. | - | - |

Square Apparels Ltd. (Subsidiary of Square Fashions Ltd.):

Opening Balance
Addition during the Period
Realized during the Period
Closing Balance

| | | |
|-----|---------------|-----------------|
| | - | - |
| | 282,037,035 | 1,020,364,484 |
| | (282,037,035) | (1,020,364,484) |
| Tk. | - | - |

C. Others:**Square InformatiX Ltd. (Service Provider):**

Opening Balance
Addition during the Period
Paid during the Period
Closing Balance (Payable)

| | | |
|-----|--------------|--------------|
| | - | - |
| | 97,160,495 | 72,613,109 |
| | (97,120,666) | (72,613,109) |
| Tk. | 39,829 | - |

Square Toiletries Ltd. (Supplier):

Opening Balance
Addition during the Period
Paid during the Period
Closing Balance (Payable)

| | | |
|-----|--------------|--------------|
| | - | - |
| | 87,297,553 | 63,409,150 |
| | (87,281,025) | (63,409,150) |
| Tk. | 16,528 | - |

Square Food & Beverages Ltd. (Supplier):

Opening Balance
Addition during the Period
Paid during the Period
Closing Balance (Payable)

| | | |
|-----|--------------|--------------|
| | - | - |
| | 81,591,004 | 51,285,349 |
| | (81,591,004) | (51,285,349) |
| Tk. | - | - |

Square Securities Management Ltd. (Port Folio Management):

Opening Balance
Addition during the Period
Realized during the Period
Closing Balance

| | | |
|-----|---------------|-----------------|
| | 10,659,741 | 121,108,758 |
| | 515,198,609 | 3,359,689,996 |
| | (479,032,337) | (3,352,506,481) |
| Tk. | 46,826,013 | 128,292,273 |

Pharma Packages (Pvt.) Ltd. (Supplier):

Opening Balance
Addition during the Period
Paid during the Period
Closing Balance (Payable)

| | | |
|-----|---------------|---------------|
| | 99,484,237 | 23,321,437 |
| | 226,436,116 | 1,315,479,070 |
| | (307,596,953) | (868,998,152) |
| Tk. | 18,323,400 | 469,802,355 |

AEGIS Services Ltd. (Service Provider):

Opening Balance
Addition during the Period
Paid during the Period
Closing Balance (Payable)

| | | |
|-----|---------------|---------------|
| | 258,720 | 1,097,545 |
| | 243,158,860 | 168,882,966 |
| | (243,417,580) | (169,980,511) |
| Tk. | - | - |



SQUARE PHARMACEUTICALS PLC.

Statement of Financial Position As at 31 December 2024

| Particulars | Notes | 31 Dec 2024 Taka | 30 Jun 2024 Taka |
|---|-------|------------------------|------------------------|
| ASSETS | | | |
| Non-Current Assets: | | | |
| Property, Plant and Equipment | 02 | 26,067,414,111 | 23,655,156,304 |
| Investment in Subsidiaries and Associates | 03 | 2,624,852,483 | 2,624,852,483 |
| Investment in Marketable Securities | 04 | 9,497,520,669 | 9,001,712,647 |
| Long Term Investment - Others | 05 | 7,532,309,610 | 6,992,206,904 |
| | | 45,722,096,873 | 42,273,928,338 |
| Current Assets: | | | |
| Inventories | 06 | 11,813,277,445 | 10,732,803,469 |
| Trade and Other Receivables | 07 | 5,093,295,100 | 4,754,218,234 |
| Advances, Deposits and Prepayments | 08 | 1,706,649,299 | 1,943,361,351 |
| Cash and Cash Equivalents | 09 | 57,959,907,771 | 52,305,603,356 |
| | | 76,573,129,615 | 69,735,986,410 |
| TOTAL ASSETS | | 122,295,226,488 | 112,009,914,748 |
| EQUITY AND LIABILITIES | | | |
| EQUITY: | | | |
| Share Capital | 10 | 8,864,510,100 | 8,864,510,100 |
| Share Premium | | 2,035,465,000 | 2,035,465,000 |
| General Reserve | | 105,878,200 | 105,878,200 |
| Fair Value Reserve | 11 | (152,564,188) | (270,973,443) |
| Retained Earnings | 12 | 93,154,343,002 | 95,060,239,763 |
| TOTAL EQUITY | | 104,007,632,114 | 105,795,119,620 |
| LIABILITIES: | | | |
| Non-Current Liabilities: | | | |
| Deferred Tax Liabilities | 13 | 585,997,481 | 625,749,549 |
| | | 585,997,481 | 625,749,549 |
| Current Liabilities: | | | |
| Trade Payables | | 510,729,170 | 686,238,794 |
| Other Payables | 14 | 15,564,534,564 | 3,512,907,803 |
| Current Tax Liabilities | 15 | 1,179,910,862 | 912,265,905 |
| Accrued Expenses | 16 | 260,310,524 | 285,649,448 |
| Unclaimed Dividend | 17 | 186,111,773 | 191,983,629 |
| | | 17,701,596,893 | 5,589,045,579 |
| TOTAL LIABILITIES | | 18,287,594,374 | 6,214,795,128 |
| TOTAL EQUITY AND LIABILITIES | | 122,295,226,488 | 112,009,914,748 |
| Net Assets Value (NAV) per Share | 26 | 117.33 | 119.35 |

The annexed notes form an integral part of these financial statements.

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Mrs. Ratna Patra
Vice-Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE PHARMACEUTICALS PLC.

Statement of Profit or Loss and Other Comprehensive Income For the Quarter Ended 31 December 2024

| Particulars | Notes | Six-Month Result | | 2nd Quarter Result | |
|---|-------|------------------------|------------------------|------------------------|------------------------|
| | | July'24 - Dec'24 | July'23 - Dec'23 | Oct'24 - Dec'24 | Oct'23 - Dec'23 |
| | | Taka | Taka | Taka | Taka |
| Net Revenue | 18 | 29,896,175,660 | 31,033,879,297 | 15,879,308,873 | 15,380,162,465 |
| Cost of Goods Sold | 19 | (17,308,352,978) | (15,732,754,009) | (9,728,323,206) | (8,119,429,613) |
| Gross Profit | | 12,587,822,682 | 15,301,125,288 | 6,150,985,667 | 7,260,732,852 |
| Selling and Distribution Expenses | 20 | (5,954,028,247) | (5,238,111,767) | (2,936,614,000) | (2,769,613,383) |
| Administrative Expenses | 21 | (881,733,530) | (820,280,584) | (443,428,396) | (455,353,040) |
| Finance Cost | | (6,203) | (16,325) | (6,203) | (16,325) |
| Operating Expenses | | (6,835,767,980) | (6,058,408,676) | (3,380,048,599) | (3,224,982,748) |
| Profit before Other Operating Income | | 5,752,054,702 | 9,242,716,612 | 2,770,937,068 | 4,035,750,104 |
| Other Operating Income | 22 | 1,713,803,860 | 1,016,584,218 | 798,650,467 | 476,890,473 |
| Profit from Operations | | 7,465,858,562 | 10,259,300,830 | 3,569,587,535 | 4,512,640,577 |
| Income from Investments | 23 | 3,053,735,856 | 2,137,688,825 | 1,589,515,211 | 1,050,282,114 |
| Profit before contribution to WPPF & WWF | | 10,519,594,418 | 12,396,989,655 | 5,159,102,746 | 5,562,922,691 |
| Contribution to WPPF & WWF | | (500,933,068) | (590,332,841) | (245,671,560) | (264,901,081) |
| Profit before Tax | | 10,018,661,350 | 11,806,656,814 | 4,913,431,186 | 5,298,021,610 |
| Current Tax (Expense) | | (2,234,244,820) | (2,526,922,772) | (1,115,747,951) | (1,042,991,071) |
| Deferred Tax (Expense) / Income | | 60,647,819 | (83,766,623) | 28,290,151 | (127,821,288) |
| Income Tax Expense | 24 | (2,173,597,001) | (2,610,689,395) | (1,087,457,800) | (1,170,812,359) |
| Profit after Tax | | 7,845,064,349 | 9,195,967,419 | 3,825,973,386 | 4,127,209,251 |
| Unrealised Gain/(Loss) on Marketable Securities | 25 | 139,305,006 | 1,849,750 | (692,655,629) | (95,856,195) |
| Deferred Tax (Expense) / Income | 13.2 | (20,895,751) | (184,975) | 103,898,344 | 9,585,619 |
| Other Comprehensive Income | | 118,409,255 | 1,664,775 | (588,757,285) | (86,270,576) |
| Total Comprehensive Income | | 7,963,473,604 | 9,197,632,194 | 3,237,216,101 | 4,040,938,676 |
| Earnings per Share (EPS) | 27 | 8.85 | 10.37 | 4.32 | 4.66 |

The annexed notes form an integral part of these financial statements.

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Mrs. Ratna Patra
Vice-Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE PHARMACEUTICALS PLC.

Statement of Changes in Equity For the Quarter Ended 31 December 2024

| Particulars | Share Capital Taka | Share Premium Taka | General Reserve Taka | Fair Value Reserve Taka | Retained Earnings Taka | Total Taka |
|-------------------------------|-----------------------|-----------------------|-------------------------|----------------------------|---------------------------|------------------------|
| As At 01 July 2023 | 8,864,510,100 | 2,035,465,000 | 105,878,200 | 734,507,296 | 88,776,603,462 | 100,516,964,058 |
| Profit after Tax | - | - | - | - | 9,195,967,419 | 9,195,967,419 |
| Other Comprehensive Income | - | - | - | 1,664,775 | - | 1,664,775 |
| Cash Dividend (2022-23) | - | - | - | - | (9,307,735,605) | (9,307,735,605) |
| As At 31 December 2023 | 8,864,510,100 | 2,035,465,000 | 105,878,200 | 736,172,071 | 88,664,835,276 | 100,406,860,647 |
| As At 01 July 2024 | 8,864,510,100 | 2,035,465,000 | 105,878,200 | (270,973,443) | 95,060,239,763 | 105,795,119,620 |
| Profit after Tax | - | - | - | - | 7,845,064,349 | 7,845,064,349 |
| Other Comprehensive Income | - | - | - | 118,409,255 | - | 118,409,255 |
| Cash Dividend (2023-24) | - | - | - | - | (9,750,961,110) | (9,750,961,110) |
| As At 31 December 2024 | 8,864,510,100 | 2,035,465,000 | 105,878,200 | (152,564,188) | 93,154,343,002 | 104,007,632,114 |

The annexed notes form an integral part of these financial statements.

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Mrs. Ratna Patra
Vice-Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE PHARMACEUTICALS PLC.

Statement of Cash Flows For the Quarter Ended 31 December 2024

| Particulars | Notes | July'24 - Dec'24 Taka | July'23 - Dec'23 Taka |
|---|-------|--------------------------|--------------------------|
| Cash Flows from Operating Activities: | | | |
| Receipts from Customers | | 34,062,799,865 | 36,837,984,047 |
| Receipts from Others | | 1,520,557,780 | 1,192,826,206 |
| Payments to Suppliers | | (13,608,261,896) | (9,924,362,115) |
| Payments for Manufacturing and Operating Expenses | | (10,951,660,475) | (9,509,486,927) |
| Payment of Value Added Tax | | (4,320,367,894) | (4,769,822,196) |
| Cash Generated from Operations | | 6,703,067,380 | 13,827,139,016 |
| Interest Paid | | (6,203) | (16,325) |
| Payment of Income Tax | | (1,766,599,863) | (1,868,199,781) |
| Payment of WPPF & WF | | (536,159,925) | (575,771,720) |
| Others | | 2,257,179,456 | 916,953,857 |
| Net Cash from Operating Activities | | 6,657,480,845 | 12,300,105,047 |
| Cash Flows from Investing Activities: | | | |
| Purchase of Property, Plant and Equipment | | (3,233,956,113) | (835,127,087) |
| Proceeds from Sale of Property, Plant and Equipment | | 22,309,355 | - |
| Long Term Investment - Others | | (540,102,706) | (1,939,594,992) |
| Investment in Marketable Securities | | (263,310,097) | (3,728,491,944) |
| Interest Received | | 2,708,416,424 | 1,762,743,936 |
| Dividends Received | 23 | 125,189,112 | 14,816,295 |
| Net Cash from/(Used in) Investing Activities | | (1,181,454,025) | (4,725,653,792) |
| Cash Flows from Financing Activities: | | | |
| Payment of Dividend | | (5,871,856) | (8,508,143) |
| Net Cash Used in Financing Activities | | (5,871,856) | (8,508,143) |
| Net Increase/(Decrease) in Cash and Cash Equivalents | | 5,470,154,964 | 7,565,943,112 |
| Cash and Cash Equivalents at 01 July | 09 | 52,305,603,356 | 50,079,192,249 |
| Effect of Exchange Rate Fluctuations on Cash and Cash Equivalents | | 184,149,451 | 78,264,044 |
| Cash and Cash Equivalents at 31 December | 09 | 57,959,907,771 | 57,723,399,404 |
| Net Operating Cash Flow (NOCF) per Share | 28 | 7.51 | 13.88 |

The annexed notes form an integral part of these financial statements.

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Mrs. Ratna Patra
Vice-Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE PHARMACEUTICALS PLC.

Notes to the Financial Statements For the Quarter Ended 31 December 2024

01. Basis of Preparation of the Interim Financial Statements:

These Financial Statements are the unaudited Interim Financial Statements of Square Pharmaceuticals PLC., a company incorporated in Bangladesh under Companies Act, 1913 for the 2nd Quarter ended on December 31, 2024. These are prepared in accordance with the International Accounting Standard (IAS-34) 'Interim Financial Reporting'. These financial statements should be read in conjunction with the Annual Financial Statements as of June 30, 2024, as they provide an update of previously reported information.

The accounting policies and presentation used are consistent with those used in the Annual Financials, except where noted below, Where necessary, the comparative figures have been reclassified or extended from the previously reported Interim Financial Statements to take into account any presentational changes made in the Annual Financial Statements or in these Interim Financial Statements.

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of revenue, expenses, assets, liabilities and disclosure of contingent liabilities at the date of the Interim Financial Statement. If in the future such estimates and assumptions, which are based on management's best judgement at the date of the Interim Financial Statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

We understand that our business is growing every year that means our assets are performing according to the intention of procurement and the discounted future cash flow from the operation of the assets would be positive if we disposed those assets at the date of financial reporting. But at present, we have no intention to dispose these assets. Therefore, it is not required to record the impairment gain as provisions of IAS-36.

The company operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the reporting period.

The company has no reportable operating segments as per IFRS-8.

Figures have been rounded off to the nearest Taka.

There is no significant event after the end of the interim period that has to be reflected in these financial statements for the interim period.

02. Property, Plant and Equipment: Tk. 26,067,414,111

Cost:

Opening Balance

Addition during the Period/Year

Disposal/Transfer during the Period/Year

Accumulated Depreciation:

Opening Balance

Charged for the Period/Year

Disposal/Transfer during the Period/Year

Net Book Value

Property, Plant and Equipment in Transit (Note - 02.1)

Building under Construction (Note - 02.2)

Written Down Value

02.1 Property, Plant and Equipment in Transit: Tk. 689,619,042

Opening Balance

Addition during the Period/Year

Transfer during the Period/Year

02.2 Building under Construction: Tk. 4,546,714,674

Opening Balance

Addition during the Period/Year

Transfer during the Period/Year

03. Investment in Subsidiaries and Associates: Tk. 2,624,852,483

03.1 Subsidiaries: Tk. 2,037,772,688

(i) Square Pharmaceuticals Kenya EPZ Ltd. (8,000,000 Ordinary Shares plus Share Money Deposit)

(ii) Square Lifesciences Ltd., Bangladesh (9,995,000 Ordinary Shares)

(iii) Samson Pharma Inc., The Philippines (139,998 Ordinary Shares)

03.2 Associates: Tk. 587,079,795

(i) Square Textiles PLC. (91,436,677 Ordinary Shares of Tk. 10/- each including Bonus Shares)

(ii) Square Hospitals Ltd. (199,750 Ordinary Shares of Tk. 1,000/- each plus Share Premium)

(iii) Square Fashions Ltd. (462,000 Ordinary Shares of Tk. 100/- each plus Share Premium)

04. Investment in Marketable Securities: Tk. 9,497,520,669

04.1 Cost:

Opening Balance

Addition during the Period/Year

Sold during the Period/Year

04.2 Market Value:

Opening Balance

Addition during the Period/Year

Sold during the Period/Year

05. Long Term Investment - Others: Tk. 7,532,309,610

05.1 Ordinary Shares (Unquoted): Tk. 127,694,430

(i) United Hospital Ltd. (120,000 Ordinary Shares of Tk.100/- each)

(ii) Central Depository Bangladesh Limited (5,711,804 Ordinary Shares of Tk. 10/- each)

(iii) FAM - First Fixed Income Fund (1,000 Units of Tk. 100,000/- each)

05.2 Non-Convertible Subordinated Bonds: Tk. 7,100,000,000

(i) Mutual Trust Bank Ltd. (220 Bonds)

(ii) Southeast Bank Ltd. (3,000 Bonds)

(iii) Islami Bank Bangladesh Ltd. (30 Bonds)

(iv) Trust Bank Ltd. (30 Bonds)

(v) Eastern Bank Ltd. (50 Bonds)

(vi) Prime Bank Ltd. (100 Bonds)

(vii) Dutch Bangla Bank Ltd. (150 Bonds)

(viii) Shahjalal Islami Bank PLC. (1000 Bonds)

05.3 Non-Convertible Zero Coupon Bonds: Tk. 304,615,180

(i) LankaBangla Finance Ltd.

(ii) Brac Bank Ltd. (200 Bonds)

(iii) IDLC Finance Ltd. (240 Bonds)

| | 31 Dec 2024 | 30 Jun 2024 |
|-----|----------------|----------------|
| | 45,591,709,620 | 43,059,540,662 |
| | 741,409,976 | 2,855,972,978 |
| | 46,333,119,596 | 45,915,513,640 |
| | (45,031,480) | (323,804,020) |
| Tk. | 46,288,088,116 | 45,591,709,620 |
| | 24,687,303,495 | 23,089,413,939 |
| | 801,112,993 | 1,728,738,883 |
| | 25,488,416,488 | 24,818,152,822 |
| | (31,408,767) | (130,849,327) |
| Tk. | 25,457,007,721 | 24,687,303,495 |
| | 20,831,080,395 | 20,904,406,125 |
| | 689,619,042 | 977,165,568 |
| | 4,546,714,674 | 1,773,584,611 |
| Tk. | 26,067,414,111 | 23,655,156,304 |
| | 977,165,568 | 715,369,536 |
| | 366,432,699 | 937,119,275 |
| | 1,343,598,267 | 1,652,488,811 |
| | (653,979,225) | (675,323,243) |
| Tk. | 689,619,042 | 977,165,568 |
| | 1,773,584,611 | 1,081,705,847 |
| | 2,773,130,063 | 1,063,055,568 |
| | 4,546,714,674 | 2,144,761,415 |
| | | (371,176,804) |
| Tk. | 4,546,714,674 | 1,773,584,611 |
| | 985,742,688 | 985,742,688 |
| | 999,500,000 | 999,500,000 |
| | 52,530,000 | 52,530,000 |
| Tk. | 2,037,772,688 | 2,037,772,688 |
| | 225,129,795 | 225,129,795 |
| | 210,750,000 | 210,750,000 |
| | 151,200,000 | 151,200,000 |
| Tk. | 587,079,795 | 587,079,795 |
| Tk. | 2,624,852,483 | 2,624,852,483 |
| | 9,320,504,933 | 3,773,747,813 |
| | 473,508,707 | 5,649,171,398 |
| | (117,005,691) | (102,414,278) |
| Tk. | 9,677,007,949 | 9,320,504,933 |
| | 9,001,712,647 | 4,589,867,031 |
| | 706,006,632 | 4,524,172,652 |
| | (210,198,610) | (112,327,036) |
| Tk. | 9,497,520,669 | 9,001,712,647 |
| | 12,000,000 | 12,000,000 |
| | 15,694,430 | 15,694,430 |
| | 100,000,000 | 100,000,000 |
| Tk. | 127,694,430 | 127,694,430 |
| | 2,200,000,000 | 2,200,000,000 |
| | 300,000,000 | 400,000,000 |
| | 300,000,000 | 400,000,000 |
| | 300,000,000 | 400,000,000 |
| | 500,000,000 | 500,000,000 |
| | 1,000,000,000 | 1,000,000,000 |
| | 1,500,000,000 | 1,500,000,000 |
| | 1,000,000,000 | - |
| Tk. | 7,100,000,000 | 6,400,000,000 |
| | - | 67,033,336 |
| | 187,659,050 | 238,677,650 |
| | 116,956,130 | 158,801,488 |
| Tk. | 304,615,180 | 464,512,474 |
| Tk. | 7,532,309,610 | 6,992,206,904 |

| | 31 Dec 2024 | 30 Jun 2024 |
|--|-----------------------|-----------------------|
| 06. Inventories: Tk. 11,813,277,445 | | |
| Raw Materials | 4,387,717,419 | 3,722,861,831 |
| Packing Materials | 1,328,322,168 | 1,091,402,281 |
| Work-in-Process | 669,632,733 | 582,783,730 |
| Finished Goods | 3,981,524,205 | 3,531,153,695 |
| Spares & Accessories | 1,154,734,000 | 951,053,588 |
| Goods- in-Transit | 291,346,920 | 853,548,344 |
| Tk. | 11,813,277,445 | 10,732,803,469 |
| 07. Trade and Other Receivables: Tk. 5,093,295,100 | | |
| Trade Receivables | 2,772,082,943 | 2,560,353,465 |
| Other Receivables (Note - 07.1) | 2,321,212,157 | 2,193,864,769 |
| Tk. | 5,093,295,100 | 4,754,218,234 |
| 07.1 Other Receivables: Tk. 2,321,212,157 | | |
| Interest Receivable from Fixed Deposit Receipts | 1,647,266,098 | 1,520,761,823 |
| Interest Receivable from Short Notice Deposits | 7,462,258 | 1,300 |
| Gain against Zero Coupon Bonds (Receivable) | 69,529,676 | 87,443,699 |
| Interest Receivable from Subordinated Bonds | 58,210,958 | 47,324,767 |
| Accrued Income | 308,743,168 | 308,333,181 |
| Insurance Claim Receivable | 230,000,000 | 230,000,000 |
| Tk. | 2,321,212,157 | 2,193,864,769 |
| 08. Advances, Deposits and Prepayments: Tk. 1,706,649,299 | | |
| 08.1 Advances: Tk. 995,627,329 | | |
| Employees | 288,035,467 | 283,810,814 |
| Advance Income Tax | - | 200,000,000 |
| Land Purchase | 91,044,000 | 84,081,400 |
| Suppliers | 616,547,862 | 576,405,123 |
| Tk. | 995,627,329 | 1,144,297,337 |
| 08.2 Deposits: Tk. 654,850,168 | | |
| Value Added Tax | 231,482,461 | 289,468,249 |
| Earnest Money & Security Deposit | 388,090,845 | 402,702,619 |
| Others | 35,276,862 | 13,001,014 |
| Tk. | 654,850,168 | 705,171,882 |
| 08.3 Prepayments: Tk. 56,171,802 | | |
| Office Rent | 22,852,440 | 23,242,440 |
| Insurance Premium | 33,319,362 | 70,649,692 |
| Tk. | 56,171,802 | 93,892,132 |
| Tk. | 1,706,649,299 | 1,943,361,351 |
| 09. Cash and Cash Equivalents: Tk. 57,959,907,771 | | |
| 09.1 Cash in Hand | | |
| 09.2 Cash at Bank: | | |
| Current Accounts | 541,920,096 | 404,685,504 |
| STD & SND Accounts | 15,009,772,474 | 14,182,411,481 |
| Export Retention Quota Accounts (held in USD) | 174,542,008 | 174,360,222 |
| Margin Held Accounts (held in USD) | 585,118,343 | 525,205,243 |
| Dividend Accounts (Note - 17) | 9,937,105,686 | 191,983,630 |
| Tk. | 26,248,458,606 | 15,478,646,080 |
| 09.3 Fixed Deposit Receipts (FDRs): | | |
| FDRs held in BDT | 27,500,381,792 | 33,000,381,792 |
| FDRs held in USD | 4,059,607,375 | 3,819,836,939 |
| Tk. | 31,559,989,167 | 36,820,218,731 |
| Tk. | 57,959,907,771 | 52,305,603,356 |
| 10. Share Capital: Tk. 8,864,510,100 | | |
| Authorised: | | |
| 1,000,000,000 Ordinary Shares of Tk. 10/- each | | |
| Paid-up: | | |
| a) Issued for Cash: | | |
| 10,092,300 Ordinary Shares of Tk. 10/- each fully paid-up in cash | 100,923,000 | 100,923,000 |
| b) Issued for Consideration other than Cash: | | |
| 40,020 Ordinary Shares of Tk. 10/- each fully paid-up for consideration other than cash | 400,200 | 400,200 |
| c) Issued as Bonus Share: | | |
| 876,318,690 Ordinary Shares of Tk. 10/- each fully paid-up as Bonus Shares | 8,763,186,900 | 8,763,186,900 |
| Tk. | 8,864,510,100 | 8,864,510,100 |
| 11. Fair Value Reserve: Tk. (152,564,188) | | |
| Opening Balance | (270,973,443) | 734,507,296 |
| Unrealised Gain/(Loss) on Marketable Securities for the Period/Year (Note - 25) | 139,305,006 | (1,134,911,504) |
| Current Period's Deferred Tax (Expense)/Income (Note - 13.2) | (20,895,751) | 129,430,765 |
| Tk. | (152,564,188) | (270,973,443) |
| 12. Retained Earnings: Tk. 93,154,343,002 | | |
| Opening Balance | 95,060,239,763 | 88,776,603,462 |
| Profit after Tax | 7,845,064,349 | 15,591,371,906 |
| Cash Dividend | (9,750,961,110) | (9,307,735,605) |
| Tk. | 93,154,343,002 | 95,060,239,763 |
| 13. Deferred Tax Liabilities: Tk. 585,997,481 | | |
| Deferred Tax - Property, Plant and Equipment (Note - 13.1) | 612,920,573 | 673,568,392 |
| Deferred Tax - Marketable Securities (Note - 13.2) | (26,923,092) | (47,818,843) |
| Tk. | 585,997,481 | 625,749,549 |
| 13.1 Deferred Tax - Property, Plant and Equipment: Tk. 612,920,573 | | |
| Carrying Amount | 12,059,773,395 | 12,418,606,865 |
| Tax Base | 9,335,681,959 | 9,424,969,566 |
| Taxable/(Deductible) Temporary Difference | 2,724,091,436 | 2,993,637,299 |
| Tax Rate | 22.50% | 22.50% |
| Closing Liability | 612,920,573 | 673,568,392 |
| Opening Liability | (673,568,392) | (944,474,683) |
| Current Period's Expense/(Income) | (60,647,819) | (270,906,291) |
| Tk. | (60,647,819) | (270,906,291) |
| * Property, plant and equipment excluding lands, PPE in transit and assets under construction. | | |
| 13.2 Deferred Tax - Marketable Securities: Tk. (26,923,092) | | |
| Carrying Amount | 9,497,520,669 | 9,001,712,647 |
| Tax Base | 9,677,007,949 | 9,320,504,933 |
| Taxable/(Deductible) Temporary Difference | (179,487,280) | (318,792,286) |
| Tax Rate | 15.00% | 15.00% |
| Closing Liability | (26,923,092) | (47,818,843) |
| Opening Liability | 47,818,843 | (81,611,922) |
| Current Period's Expense/(Income) | 20,895,751 | (129,430,765) |
| Tk. | 20,895,751 | (129,430,765) |

| | 31 Dec 2024 | 30 Jun 2024 |
|---|-------------------------|-------------------------|
| 14. Other Payables: Tk. 15,564,534,564 | | |
| Sundry Creditors | 4,829,192,572 | 2,494,687,117 |
| Income Tax (Deduction at Source) | 15,018,771 | 13,630,694 |
| Retention Money | 10,196,815 | 10,197,839 |
| Dividend Payable | 9,750,961,110 | - |
| Workers' Profit Participation Fund and Welfare Fund | 959,165,296 | 994,392,153 |
| Tk. 15,564,534,564 | 3,512,907,803 | |
| 15. Current Tax Liabilities: Tk. 1,179,910,862 | | |
| Opening Balance | 912,265,905 | 356,095,553 |
| Provision made for the Period/Year | 2,234,244,820 | 4,567,377,453 |
| Payment made during the Period/Year | (1,966,599,863) | (4,011,207,101) |
| Tk. 1,179,910,862 | 912,265,905 | |
| 16. Accrued Expenses: Tk. 260,310,524 | | |
| Accrued Expenses | 260,210,524 | 284,549,448 |
| Audit Fees | 100,000 | 1,100,000 |
| Tk. 260,310,524 | 285,649,448 | |
| 17. Unclaimed Dividend: Tk. 186,111,773 | | |
| Opening Balance | 191,983,629 | 158,997,790 |
| Addition during the Period/Year | - | 81,227,751 |
| Paid to shareholders during the Period/Year | (5,871,856) | (10,542,278) |
| Transferred to CMS Fund during the Period/Year | - | (37,699,634) |
| Tk. 186,111,773 | 191,983,629 | |
| | July'24 - Dec'24 | July'23 - Dec'23 |
| 18. Net Revenue: Tk. 29,896,175,660 | | |
| Local: | | |
| Gross Revenue | 33,993,741,858 | 36,293,651,905 |
| Value Added Tax | (4,378,353,682) | (5,256,967,590) |
| Revenue without VAT | 29,615,388,176 | 31,036,684,315 |
| Discount | (1,112,071,225) | (1,173,029,422) |
| Net Revenue - Local | 28,503,316,951 | 29,863,654,893 |
| Export Revenue - Equivalent to US \$11,661,087 (Jul'23-Dec'23: US \$11,525,880) | 1,392,858,710 | 1,170,224,404 |
| Tk. 29,896,175,660 | 31,033,879,297 | |
| 19. Cost of Goods Sold: Tk. 17,308,352,978 | | |
| Raw Materials Consumed (Note - 19.1) | 7,369,307,698 | 6,782,599,373 |
| Packing Materials Consumed (Note - 19.2) | 3,874,825,721 | 3,430,377,619 |
| Cost of Materials Consumed | 11,244,133,419 | 10,212,976,991 |
| Add: Manufacturing Overhead (Note - 19.3) | 4,774,670,118 | 4,077,411,591 |
| Total Manufacturing Cost | 16,018,803,537 | 14,290,388,582 |
| Add: Opening Work-in-Process | 582,783,730 | 534,754,619 |
| Less: Closing Work-in-Process | (669,632,733) | (528,709,822) |
| Cost of Goods Manufactured | 15,931,954,534 | 14,296,433,379 |
| Add: Opening Finished Goods | 3,531,153,695 | 3,322,480,192 |
| Add: Purchase of Finished Goods | 1,937,318,643 | 1,736,673,630 |
| Less: Cost of Physician Sample | (110,549,689) | (112,724,181) |
| Cost of Goods Available for Sale | 21,289,877,183 | 19,242,863,021 |
| Less: Closing Finished Goods | (3,981,524,205) | (3,510,109,012) |
| Tk. 17,308,352,978 | 15,732,754,009 | |
| 19.1 Raw Materials Consumed: Tk. 7,369,307,698 | | |
| Opening Stock | 3,722,861,831 | 3,389,777,254 |
| Purchased during the Period | 8,034,163,286 | 6,570,003,972 |
| Closing Stock | (4,387,717,419) | (3,177,181,853) |
| Tk. 7,369,307,698 | 6,782,599,373 | |
| 19.2 Packing Materials Consumed: Tk. 3,874,825,721 | | |
| Opening Stock | 1,091,402,281 | 1,059,984,113 |
| Purchased during the Period | 4,111,745,608 | 3,354,954,866 |
| Closing Stock | (1,328,322,168) | (984,561,360) |
| Tk. 3,874,825,721 | 3,430,377,619 | |
| 19.3 Manufacturing Overhead: Tk. 4,774,670,118 | | |
| Salaries & Allowances | 1,589,180,038 | 1,337,966,975 |
| Contribution to Provident Fund | 47,408,850 | 31,678,309 |
| Entertainment, Staff Lunch & Refreshments | 91,190,524 | 73,915,665 |
| Training & Development | 636,753 | 356,224 |
| Staff Uniform | 58,913,847 | 57,360,633 |
| Travelling & Conveyance | 31,392,277 | 24,980,327 |
| US FDA User Fees | 82,628,520 | 73,149,378 |
| Laboratory Consumables | 342,875,259 | 315,889,087 |
| Research & Product Development | 186,586,709 | 62,372,698 |
| Printing & Stationery | 45,414,117 | 41,005,558 |
| Courier, Telephone, Cell phone & Internet | 5,137,423 | 5,028,516 |
| Rental Expenses | 649,710 | 605,110 |
| Utilities Expense | 618,126,215 | 584,342,018 |
| Sanitation Expenses | 107,738,866 | 63,238,294 |
| Petrol, Oil & Lubricants | 138,193,590 | 87,819,117 |
| Generator Rental Expenses | 18,000,000 | 7,300,000 |
| Repairs & Maintenance - Factory | 586,586,092 | 500,084,445 |
| Repairs & Maintenance - Vehicle | 61,171,837 | 57,262,452 |
| Insurance Premium | 21,809,114 | 20,745,197 |
| Security Services | 41,990,553 | 31,975,427 |
| Govt. Taxes & License Fees | 15,043,055 | 16,355,759 |
| Toll Charges | 81,819,230 | 36,412,074 |
| Software, Hardware Support & VSAT Services | 33,577,747 | 27,007,430 |
| Depreciation | 567,291,590 | 620,303,227 |
| Other Expenses | 1,308,202 | 257,671 |
| Tk. 4,774,670,118 | 4,077,411,591 | |

| | July'24 - Dec'24 | July'23 - Dec'23 |
|---|----------------------|----------------------|
| 20. Selling and Distribution Expenses: Tk. 5,954,028,247 | | |
| Salaries & Allowances | 945,117,527 | 848,583,397 |
| Contribution to Provident Fund | 78,042,481 | 60,994,263 |
| Entertainment, Staff Lunch & Refreshments | 22,240,509 | 21,839,082 |
| Training & Development | 5,838,983 | 4,956,575 |
| Staff Uniform | 3,518,860 | 3,173,253 |
| Travelling & Conveyance | 89,216,063 | 86,468,101 |
| Printing & Stationery | 49,425,366 | 43,723,162 |
| Courier, Telephone, Cell phone & Internet | 49,894,682 | 40,969,944 |
| Office & Godown Rent | 18,981,083 | 16,581,826 |
| Utilities Expense | 25,531,125 | 22,245,556 |
| Sanitation Expenses | 10,897,599 | 10,313,091 |
| Field Staff Salaries, Allowances, TA & DA | 1,947,780,246 | 1,794,297,785 |
| Target Incentive to Field Staff | 233,992,009 | 247,254,859 |
| Promotional Expenses | 563,300,475 | 587,511,689 |
| Marketing Expenses | 607,188,114 | 335,496,810 |
| Pharmacovigilance | 34,073,829 | 78,803,319 |
| Marketing Website Platform Software Maintenance | 7,535,633 | 5,651,840 |
| Event, Programs & Conference | 146,957,044 | 105,564,370 |
| Literature & Publications | 88,184,557 | 68,021,022 |
| Market Research & Survey Expenses | 12,661,447 | 9,247,561 |
| Advertisement | 756,000 | 130,000 |
| Delivery & Packing Expenses | 152,594,665 | 131,999,496 |
| Export Expenses | 165,881,949 | 65,605,851 |
| Repairs & Maintenance - Office | 35,899,902 | 32,919,121 |
| Repairs & Maintenance - Vehicle | 302,250,877 | 283,765,181 |
| Insurance Premium | 3,162,593 | 2,939,048 |
| Security Services | 56,537,996 | 47,617,220 |
| Govt. Taxes & License Fees | 26,519,661 | 18,327,656 |
| Bank Charges | 8,181,733 | 8,708,194 |
| Software, Hardware Support & VSAT Services | 37,763,617 | 26,517,737 |
| Depreciation | 113,389,371 | 114,963,266 |
| Other Expenses | 110,712,251 | 112,921,492 |
| Tk. | 5,954,028,247 | 5,238,111,767 |
| 21. Administrative Expenses: Tk. 881,733,530 | | |
| Salaries & Allowances | 291,434,411 | 262,263,484 |
| Contribution to Provident Fund | 7,482,640 | 5,954,709 |
| Directors' Remuneration | 44,437,500 | 44,437,500 |
| Entertainment, Staff Lunch & Refreshments | 39,045,477 | 35,589,139 |
| Training & Development | 3,288,068 | 3,019,293 |
| Staff Uniform | 904,725 | 851,579 |
| Travelling & Conveyance | 90,163,957 | 80,098,529 |
| Printing & Stationery | 10,642,980 | 9,844,967 |
| Courier, Telephone, Cell phone & Internet | 6,628,549 | 5,004,918 |
| Office Rent | 13,085,082 | 10,172,688 |
| Utilities Expense | 16,995,909 | 14,075,250 |
| Sanitation Expenses | 5,588,248 | 4,769,009 |
| Subscription & Donation | 2,615,200 | 2,435,000 |
| Legal & Professional Fees | 3,840,167 | 1,851,850 |
| Repairs & Maintenance - Office | 103,545,407 | 94,162,270 |
| Repairs & Maintenance - Vehicle | 43,819,490 | 39,754,375 |
| Insurance Premium | 14,562,520 | 12,293,026 |
| Security Services | 33,670,507 | 26,894,678 |
| Govt. Taxes & License Fees | 15,272,035 | 38,125,489 |
| Bank Charges | 3,634,591 | 4,945,514 |
| Software & Hardware Support Services | 4,469,501 | 5,355,675 |
| Depreciation | 120,432,032 | 114,571,004 |
| Other Expenses | 6,174,534 | 3,810,638 |
| Tk. | 881,733,530 | 820,280,584 |
| 22. Other Operating Income: Tk. 1,713,803,860 | | |
| Rental Income | 8,187,708 | 8,076,706 |
| Sale of Scrap | 30,972,838 | 26,181,401 |
| Gain on Fluctuation of Foreign Currency | 184,149,451 | 94,290,139 |
| Cash Incentive Received against Export | 2,417,200 | 22,924,800 |
| Commission Received | 1,478,455,972 | 864,849,919 |
| P.F Forfeiture Amount | 934,049 | 261,253 |
| Gain/(Loss) on Disposal of Property, Plant and Equipment | 8,686,642 | - |
| Tk. | 1,713,803,860 | 1,016,584,218 |
| 23. Income from Investments: Tk. 3,053,735,856 | | |
| Interest from Deposits | 1,810,992,019 | 1,472,360,382 |
| Interest from Short Notice Deposits | 671,593,561 | 407,895,069 |
| Gain on Redemption of Zero Coupon Bond | 17,688,683 | 34,547,098 |
| Interest from Subordinate Bonds | 335,079,562 | 207,217,424 |
| Dividend Income | 125,189,112 | 14,816,295 |
| Gain on Sale of Marketable Securities (Realized) | 93,192,919 | 852,558 |
| Tk. | 3,053,735,856 | 2,137,688,825 |
| 24. Income Tax Expenses: Tk. 2,173,597,001 | | |
| Current Tax Expense | 2,234,244,820 | 2,526,922,772 |
| Deferred Tax Expense / (Income) | (60,647,819) | 83,766,623 |
| Tk. | 2,173,597,001 | 2,610,689,395 |
| 24.1 Reconciliation of Effective Tax Rate: | | |
| Profit before Tax | | |
| Income Tax using Corporate Tax Rate | 22.50% | 22.50% |
| Effects of: | | |
| Income Exempted from Tax | -0.45% | -0.07% |
| Income Taxed at Reduced Rate | -0.35% | -0.32% |
| Effective Income Tax | 21.70% | 22.11% |
| Effect of Deferred Tax | 0.61% | -0.71% |
| Effective Current Tax | 22.30% | 21.40% |
| 25. Unrealised Gain/(Loss) on Marketable Securities: Tk. 139,305,006 | | |
| Closing Unrealised Gain/(Loss) | (179,487,280) | 817,968,968 |
| Less: Opening Unrealised Gain/(Loss) | (318,792,286) | 816,119,218 |
| Tk. | 139,305,006 | 1,849,750 |

| | July'24 - Dec'24 | July'23 - Dec'23 |
|---|--------------------------|-----------------------|
| 26. Net Asset Value (NAV) per Share: Tk. 117.33 | | |
| Net Asset attributable to the Ordinary Shareholders | 104,007,632,114 | 105,795,119,620 |
| Number of Shares outstanding | 886,451,010 | 886,451,010 |
| Tk. | 117.33 | 119.35 |
| 27. Earnings per Share (EPS): Tk. 8.85 | | |
| Net Profit after Tax attributable to Shareholders | 7,845,064,349 | 9,195,967,419 |
| Number of Shares outstanding | 886,451,010 | 886,451,010 |
| Tk. | 8.85 | 10.37 |
| 28. Net Operating Cash Flow (NOCF) per Share: Tk. 7.51 | | |
| Net Cash Generated from Operating Activities (Note - 28.1) | 6,657,480,845 | 12,300,105,047 |
| Number of Shares outstanding | 886,451,010 | 886,451,010 |
| Tk. | 7.51 | 13.88 |
| Due to Eid holiday in June 2023, additional credit facility were provided to the local customers which were collected during July'23 - Dec'23. Additionally, the Company received Insurance claim against the fire incident of LVP. These two factors caused a spike in the NOCF per share in July'23- Dec'23. There is no such factors in this period. Therefore, the NOCF per share seen a decline in the current period. | | |
| 28.1 Reconciliation of Net Profit with Cash Flows Generated from Operating Activities: | | |
| Profit after Tax | 7,845,064,349 | 9,195,967,419 |
| Adjustments for: | | |
| Non-Cash Income/Expenses: | | |
| Depreciation | 801,112,993 | 849,837,496 |
| Effect of Exchange Rate Fluctuations | (184,149,451) | (78,264,046) |
| Deferred Tax (Expense) / Income | (60,647,819) | 83,766,623 |
| | 556,315,723 | 855,340,073 |
| Non-Operating Income/Expenses: | | |
| Income from Investments (Note - 23) | (3,053,735,856) | (2,137,688,825) |
| (Gain)/Loss on Disposal of Property, Plant and Equipment (Note - 22) | (8,686,642) | - |
| | (3,062,422,498) | (2,137,688,825) |
| Changes in Working Capital: | | |
| (Increase)/Decrease in Current Assets: | | |
| Inventories | (1,080,473,976) | (37,061,544) |
| Trade Receivables | (211,729,478) | 575,278,010 |
| Other Receivables | (409,987) | 1,160,324,506 |
| Advances, Deposits and Prepayments | 43,674,652 | 96,458,749 |
| Increase/(Decrease) in Current Liabilities: | | |
| Trade Payables | (175,509,624) | 1,804,362,117 |
| Other Payables | 2,300,665,651 | (21,131,272) |
| Current Tax Liabilities | 467,644,957 | 658,722,991 |
| Accrued Expenses | (25,338,924) | 149,532,823 |
| | 1,318,523,271 | 4,386,486,380 |
| Net Cash from Operating Activities | Tk. 6,657,480,845 | 12,300,105,047 |
| 29. Contingent Liabilities: | | |
| 1. Liabilities for at Sight Letter of Credits as of 31 December 2024 was Tk. 7,283,395,575. | | |
| 2. Corporate Guarantee in favour of Square Pharmaceuticals Kenya EPZ Ltd. for USD 8.00 Million is still in place with due approval of Bangladesh Bank. | | |
| 30. Related Party Transactions: | | |
| 30.1 Transaction with Key Management Personnel: | | |
| Amount of compensation paid to Key Management Personnel including Board of Directors during the Period: | | |
| Short-Term Employee Benefits | Tk. 245,508,915 | 220,019,420 |
| Post-Employment Benefits | Tk. 4,619,095 | 12,618,525 |
| Other Long-Term Benefits | - | - |
| Termination Benefits | - | - |
| Share-Based Payment | - | - |
| 30.2 Transaction with Other Related parties: | | |
| A. Associates: | | |
| Square Textiles Ltd. (46.36% share): | | |
| Opening Balance | - | - |
| Addition during the Period | 5,386,200,000 | 2,946,700,000 |
| Realized during the Period | (5,386,200,000) | (1,467,548,000) |
| Tk. | - | 1,479,152,000 |
| Square Fashions Ltd. (48.63% share): | | |
| Opening Balance | - | - |
| Addition during the Period | 11,846,581,422 | 3,121,635,221 |
| Realized during the Period | (11,846,581,422) | (3,162,284,043) |
| Tk. | - | (40,648,822) |
| Square Hospitals Ltd. (49.94% share): | | |
| Opening Balance | - | - |
| Addition during the Period | 22,752,620 | 19,093,077 |
| Realized during the Period | (22,752,620) | (19,093,077) |
| Tk. | - | - |
| B. Subsidiaries: | | |
| Square Lifesciences Ltd. (99.95% share): | | |
| Opening Balance | (1,616,263,960) | 2,429,691,285 |
| Addition during the Period | 8,594,445,852 | 4,612,813,802 |
| Realized during the Period | (10,712,247,475) | (6,439,988,040) |
| Tk. | (3,734,065,583) | 602,517,047 |
| C. Subsidiaries of Associates: | | |
| Square Denims Ltd. (Subsidiary of Square Fashions Ltd.): | | |
| Opening Balance | - | - |
| Addition during the Period | 778,781,543 | 819,568,800 |
| Realized during the Period | (778,781,543) | (819,568,800) |
| Tk. | - | - |
| Square Apparels Ltd. (Subsidiary of Square Fashions Ltd.): | | |
| Opening Balance | - | - |
| Addition during the Period | 279,637,035 | 987,616,079 |
| Realized during the Period | (279,637,035) | (987,616,079) |
| Tk. | - | - |
| D. Others: | | |
| Square InformatiX Ltd. (Service Provider): | | |
| Opening Balance | - | - |
| Addition during the Period | 95,681,244 | 72,613,109 |
| Realized during the Period | (95,681,244) | (72,613,109) |
| Tk. | - | - |

Square Toiletries Ltd. (Supplier):

Opening Balance
Addition during the Period
Realized during the Period

| | July'24 - Dec'24 | July'23 - Dec'23 |
|-----|------------------|------------------|
| | - | - |
| | 87,214,911 | 63,354,650 |
| | (87,214,911) | (63,354,650) |
| Tk. | - | - |

Square Food & Beverages Ltd. (Supplier):

Opening Balance
Addition during the Period
Realized during the Period

| | | |
|-----|--------------|--------------|
| | - | - |
| | 81,591,004 | 51,285,349 |
| | (81,591,004) | (51,285,349) |
| Tk. | - | - |

Square Securities Management Ltd. (Portfolio Manager):

Opening Balance
Addition during the Period
Realized during the Period

| | | |
|-----|---------------|-----------------|
| | 10,037,386 | 121,108,758 |
| | 460,198,609 | 3,313,589,996 |
| | (423,421,019) | (3,306,447,613) |
| Tk. | 46,814,976 | 128,251,141 |

Pharma Packages (Pvt.) Ltd. (Supplier):

Opening Balance
Addition during the Period
Realized during the Period

| | | |
|-----|---------------|---------------|
| | 71,489,278 | 5,746,842 |
| | 161,730,651 | 1,247,874,182 |
| | (223,485,460) | (800,000,000) |
| Tk. | 9,734,469 | 453,621,024 |

AEGIS Services Ltd. (Service Provider):

Opening Balance
Addition during the Period
Realized during the Period

| | | |
|-----|---------------|---------------|
| | - | - |
| | 231,276,924 | 161,994,074 |
| | (231,276,924) | (161,994,074) |
| Tk. | - | - |